Can current treatments for advanced non-small-cell lung cancer be improved?

JAMA

Volumn 292, Issue 4, 2004, Pages 499-500

  Argiris, Athanassios ^a   Schiller, Joan H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HUMAN; LUNG CANCER; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; SMOKING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 3242782550     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.4.499     Document Type: Editorial

References (13)

1. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst. 2004;96:99-106.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64, 31.
3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
4. Shanafelt TD, Loprinzi C, Marks R, Novotny P, Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol. 2004;22:1966-1974.
5. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol. 2002;20(18 suppl):23S-33S.
6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
7. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470-484.
8. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2001;2:475-482.
9. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med. 1973;288:998-1006.
10. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustard in the palliative treatment of carcinoma with a particular reference to bronchogenic carcinoma. Cancer. 1948;1:634-656.
11. Ramalingam S, Belani CP. Basic treatment considerations: chemotherapy. Hematol Oncol Clin North Am. 2004;18:13-28.
12. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth facto receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-2158.
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.